Link to this page
Multiple sclerosis ontology
Last uploaded:
November 11, 2014
Jump to:
| Preferred Name | Daclizumab | |
| Synonyms |
|
|
| ID |
http://scai.fraunhofer.de/MSOntology#Daclizumab |
|
| Context |
Drug : DBA000107
|
|
| isDefinedBy |
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.
|
|
| prefixIRI |
MSOntology:Daclizumab
|
|
| prefLabel |
Daclizumab
|
|
| Reference | ||
| subClassOf |
http://scai.fraunhofer.de/MSOntology#Disease_modifying_drugs |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping